Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Dasher Neuroscience Holdings's PB Ratio or its related term are showing as below:
ROCO:7829'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 3.39
Current: 3.29
During the past 4 years, Dasher Neuroscience Holdings's highest PB Ratio was 3.39. The lowest was 0.00. And the median was 0.00.
ROCO:7829's PB Ratio is ranked worse than 72.02% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.91
vs ROCO:7829: 3.29
During the past 12 months, Dasher Neuroscience Holdings's average Book Value Per Share Growth Rate was 57.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 282.60% per year.
During the past 4 years, the highest 3-Year average Book Value Per Share Growth Rate of Dasher Neuroscience Holdings was 282.60% per year. The lowest was 282.60% per year. And the median was 282.60% per year.
Back to Basics: PB Ratio
Dasher Neuroscience Holdings (ROCO:7829) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Dasher Neuroscience Holdings PB Ratio Related Terms
Dasher Neuroscience Holdings PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Dasher Neuroscience Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dasher Neuroscience Holdings PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dasher Neuroscience Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Dasher Neuroscience Holdings's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Dasher Neuroscience Holdings (ROCO:7829) has a PB Ratio of 3.30 as of Jul. 17, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Dasher Neuroscience Holdings and its competitors. According to the industry distribution chart, Dasher Neuroscience Holdings ranks #664 out of 922 companies in the Drug Manufacturers industry, placing it in the top 72%.
Is Dasher Neuroscience Holdings' PB Ratio too high?
Dasher Neuroscience Holdings' current PB Ratio is 3.30. The Drug Manufacturers industry median PB Ratio is 1.91. Dasher Neuroscience Holdings' value of 3.30 is 72.8% above this industry median. Based on the distribution chart, Dasher Neuroscience Holdings ranks #664 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Dasher Neuroscience Holdings has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Dasher Neuroscience Holdings' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dasher Neuroscience Holdings ranks #664 out of 922 companies for PB Ratio. This places Dasher Neuroscience Holdings in the lower half of its industry. The industry median PB Ratio is 1.91. Dasher Neuroscience Holdings' value of 3.30 is 72.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.91, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dasher Neuroscience Holdings's current PB Ratio of 3.30 is 72.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Dasher Neuroscience Holdings and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dasher Neuroscience Holdings's current PB Ratio is 3.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dasher Neuroscience Holdings stock overvalued right now?
Dasher Neuroscience Holdings (ROCO:7829) has a current PB Ratio of 3.30. The current PB Ratio is 3.30 and 72.8% above the Drug Manufacturers industry median of 1.91. Dasher Neuroscience Holdings' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Dasher Neuroscience Holdings (ROCO:7829), the current PB Ratio is 3.30 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Yoda Pharmaceuticals Inc is a pharmaceutical company specializing in using AI technology to develop drugs targeting Central Nervous System (CNS) disorders. The group provides solutions for Neurology, Neuropsychiatry, and Cerebrovascular Disease.
14GF Score
Get the complete analysis for ROCO:7829
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7829 has been successfully added to your 
